Analysis of Platelet and Monocyte-to-lymphocyte Ratio and Diabetes Mellitus with Benign Prostatic Enlargement

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jul 26

PMID 37492582

Authors

Guanheng Chen

Leiguang Feng

Affiliations

Soon will be listed here.

Abstract

Background: The etiology of benign prostatic hyperplasia (BPH) is still elusive. The aim of this study was to provide preventive and prognostic parameters associated with diabetes mellitus with benign prostatic enlargement (BPE).

Methods: Diabetic patients were collected retrospectively from February 2021 to December 2022, including monocyte-to-lymphocyte ratio (MLR). Diabetic patients were divided into two groups by whether the prostate volume was greater than or equal to 30 ml, which were diabetes mellitus without BPE (DM) and diabetes mellitus with BPE (DM+BPE). The baseline characteristics were compared, the risk and protective factors associated with DM+BPE were determined using univariate and multivariate logistic regression, and the parameters associated with prostate volume were determined using correlation analysis.

Results: Of the 671 patients collected, age and prostate volume were significantly higher in the DM+BPE than in the DM; MLR was higher in the DM+BPE than in the DM; and platelet was significantly lower in the DM+BPE than in the DM. Univariate logistic regression showed that age was a risk factor, while protective factors for DM+BPE were lymphocytes and platelet. Multifactorial logistic regression showed that age was a risk factor, while platelet was the protective factor for DM+BPE. In the total overall (n=671), prostate volume was positively correlated with age. Prostate volume was negatively correlated with lymphocytes and platelet. In DM+BPE (n=142), prostate volume was positively correlated with age and MLR.

Conclusion: Platelet was a protective factor for DM+BPE and was negatively correlated with prostate volume, whereas MLR was positively correlated with prostate volume in DM+BPE.

Citing Articles

The relationship between complete blood cell count-derived inflammatory biomarkers and benign prostatic hyperplasia in middle-aged and elderly individuals in the United States: Evidence from NHANES 2001-2008.

Shi C, Cao H, Zeng G, Yang L, Wang Y PLoS One. 2024; 19(7):e0306860.

PMID: 38980876 PMC: 11233019. DOI: 10.1371/journal.pone.0306860.

Association between monocyte-to-lymphocyte ratio and prostate cancer in the U.S. population: a population-based study.

Wang L, Li X, Liu M, Zhou H, Shao J Front Cell Dev Biol. 2024; 12:1372731.

PMID: 38645410 PMC: 11026607. DOI: 10.3389/fcell.2024.1372731.

References

Pandolfo S, Del Giudice F, Chung B, Manfredi C, De Sio M, Damiano R . Robotic assisted simple prostatectomy versus other treatment modalities for large benign prostatic hyperplasia: a systematic review and meta-analysis of over 6500 cases. Prostate Cancer Prostatic Dis. 2022; 26(3):495-510. DOI: 10.1038/s41391-022-00616-4. View

Chen Y, Cai J, Zhang M, Yan X . Prognostic Role of NLR, PLR and MHR in Patients With Idiopathic Pulmonary Fibrosis. Front Immunol. 2022; 13:882217. PMC: 9096781. DOI: 10.3389/fimmu.2022.882217. View

Cao X, Shang Y, Kong W, Jiang S, Liao J, Dai R . Flavonoids derived from Anemarrhenae Rhizoma ameliorate inflammation of benign prostatic hyperplasia via modulating COX/LOX pathways. J Ethnopharmacol. 2021; 284:114740. DOI: 10.1016/j.jep.2021.114740. View

Duarsa G, Sari Y, Gde Oka A, Santosa K, Yudiana I, Tirtayasa P . Serum testosterone and prostate-specific antigen levels are major risk factors for prostatic volume increase among benign prostatic hyperplasia patients. Asian J Urol. 2021; 8(3):289-297. PMC: 8356038. DOI: 10.1016/j.ajur.2020.06.001. View

Choi J, Min S . Complicated urinary tract infection in patients with benign prostatic hyperplasia. J Infect Chemother. 2021; 27(9):1284-1287. DOI: 10.1016/j.jiac.2021.06.006. View

Devlin C, Simms M, Maitland N . Benign prostatic hyperplasia - what do we know?. BJU Int. 2020; 127(4):389-399. DOI: 10.1111/bju.15229. View

Huang J, Chan C, Yee S, Deng Y, Bai Y, Chan S . Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022; 26(2):421-428. DOI: 10.1038/s41391-022-00610-w. View

Kang J, Choi J, Cho J, Yoo T, Park Y, Lee J . Association of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Lymphocyte-to-Monocyte Ratio with Benign Prostatic Hyperplasia: A Propensity Score-Matched Analysis. Urol Int. 2021; 105(9-10):811-816. DOI: 10.1159/000512894. View

Avci S, Onen E, Caglayan V, Kilic M, Sambel M, Oner S . Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer. Arch Ital Urol Androl. 2020; 92(1):1-6. DOI: 10.4081/aiua.2020.1.1. View

10.

Lerner L, McVary K, Barry M, Bixler B, Dahm P, Das A . Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II-Surgical Evaluation and Treatment. J Urol. 2021; 206(4):818-826. DOI: 10.1097/JU.0000000000002184. View

11.

Tian Y, Liu H, Yang B, Yang X, Sun Z, Sun F . Prostatic anatomical parameters correlate with clinical characteristics suggestive of benign prostatic hyperplasia. Asian J Androl. 2020; 23(1):64-68. PMC: 7831844. DOI: 10.4103/aja.aja_47_20. View

12.

Liu Y, Wang Z, Gan Y, Chen X, Zhang B, Chen Z . Curcumin attenuates prostatic hyperplasia caused by inflammation up-regulation of bone morphogenetic protein and activin membrane-bound inhibitor. Pharm Biol. 2021; 59(1):1026-1035. PMC: 8354175. DOI: 10.1080/13880209.2021.1953539. View

13.

Jia L, Strand D, Goueli R, Gahan J, Roehrborn C, Mauck R . PSA density is associated with BPH cellular composition. Prostate. 2022; 82(12):1162-1169. PMC: 9329225. DOI: 10.1002/pros.24367. View

14.

Foster H, Dahm P, Kohler T, Lerner L, Parsons J, Wilt T . Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2019. J Urol. 2019; 202(3):592-598. DOI: 10.1097/JU.0000000000000319. View

15.

Sarma A, Wei J . Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012; 367(3):248-57. DOI: 10.1056/NEJMcp1106637. View

16.

Jin B, Ju J, Nugroho A, Lee M, An H . Carica papaya leaf extract inhibits prostatitis-associated prostatic hyperplasia via the TRAF6/TAK1/MEK/NF-κB pathway. Biomed Pharmacother. 2021; 135:111197. DOI: 10.1016/j.biopha.2020.111197. View

17.

Cakir S, Ozcan L, Polat E, Besiroglu H, Kocaaslan R, Otunctemur A . Statins are effective in the treatment of benign prostatic hyperplasia with metabolic syndrome. Aging Male. 2018; 23(5):538-543. DOI: 10.1080/13685538.2018.1541979. View

18.

Zeng Z, Zhan J, Zhang K, Chen H, Cheng S . Global, regional, and national burden of urinary tract infections from 1990 to 2019: an analysis of the global burden of disease study 2019. World J Urol. 2022; 40(3):755-763. DOI: 10.1007/s00345-021-03913-0. View

19.

Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A . The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013; 112(4):432-41. DOI: 10.1111/bju.12118. View

20.

Jahan N, Chowdhury A, Li T, Xu K, Wei F, Wang S . Neferine improves oxidative stress and apoptosis in benign prostate hyperplasia via Nrf2-ARE pathway. Redox Rep. 2021; 26(1):1-9. PMC: 7808392. DOI: 10.1080/13510002.2021.1871814. View